Human Formulations

White Soft Parafin 13.2%w/w + light Liquid Paraffin 10.2°/0w/w*Glycerine + Methyl Paraben 0.1147%w/w* Propyl Paraben 0.014°/ow/w

White Soft Parafin 13.2%w/w + light Liquid Paraffin 10.2°/0w/w*Glycerine + Methyl Paraben 0.1147%w/w* Propyl Paraben 0.014°/ow/w is a topical formulation formulated with White Soft Parafin 13.2%w/w + light Liquid Paraffin 10.2°/0w/w*Glycerine + Methyl Par

Topical FormulationsOintment & Cream Single Ingredient Topical Formulation
Sterile injectable formulation

Product information

Product Line
Human Formulations
Category
Topical Formulations, Ointment & Cream
Dosage Form
Topical Formulation
Product Type
Single Ingredient

Available strengths

White Soft Parafin 13.2%w/w + light Liquid Paraffin 10.2°/0w/w*Glycerine + Methyl Paraben 0.1147%w/w* Propyl Paraben 0.014°/ow/w

Description

White Soft Parafin 13.2%w/w + light Liquid Paraffin 10.2°/0w/w*Glycerine + Methyl Paraben 0.1147%w/w* Propyl Paraben 0.014°/ow/w is a topical formulation formulated with White Soft Parafin 13.2%w/w + light Liquid Paraffin 10.2°/0w/w*Glycerine + Methyl Paraben 0.1147%w/w* Propyl Paraben 0.014°/ow/w. The listed active ingredient profile is White Soft Parafin w/w; light Liquid Paraffin °/ *Glycerine; Methyl Paraben w/w* Propyl Paraben °/ow/w, placing the product in the skin protectant / emollient category. The formulation contains soothing, protective and/or emollient ingredients intended to support dry, irritated or protected skin. The dosage form is intended for topical/local application; the exact application site and frequency must follow the approved product instructions. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.
WHO-GMP Sourced
Sterile Supply
Regulatory Documentation
Quality Assured